56 results about "Ototoxicity" patented technology

Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity.

The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects.

The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ototoxicity, by administering these compounds or pharmaceutical compositions to subjects in need thereof. Ototoxicity is defined as damage to the structures of the ear, such as the cochlea and vestibular system, by drugs or toxins. Ototoxicity can result in irreversible hearing loss, tinnitus, dysequilibrium, Meniere's disease, or vertigo.

Loss of bilateral vestibular function is a chronic disease that may result from ototoxic, infectious, traumatic, autoimmune, or congenital causes. The purpose of the present invention is to improve the effectiveness of a vibrotactile feedback device. The present invention provides a vibrotactile feedback device for arrangement to a human body, comprising: a sensor arranged to sense a current posture of the human body relative to an environment; a haptic actuator arranged to allow the human body to perceive a posture deviation; an elongate carrier for holding the haptic actuator and the sensor in haptic communication with the human body and for holding the haptic actuator and the sensor substantially fixed relative to the human body; and a processing unit configured to: receive the current pose from the sensor; determining the posture deviation based on comparing the desired posture of the human body with the current posture; and transmitting an actuation signal to one or more of the haptic actuators based on the attitude deviation; wherein the haptic actuator is arranged to the carrier such that the haptic actuator is substantially arranged in a reference plane when the carrier is used; wherein the reference surface is functionally perpendicular to a central axis of a torso of the human body, and the reference surface intersects the torso to define a circumference to which the haptic actuators are arranged; and wherein the carrier comprises a stretchable material such that the relative distance between the haptic actuators and / or between the haptic actuators and the sensor is maintained irrespective of the length of the circumference.

Provided herein are methods for preventing and / or reducing the severity of drug induced ototoxicity. Provided herein are methods for recovery from hearing loss due to drug-induced ototoxicity.

Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and preventing inflammatory pain are described.

A method of treating inner ear hardness of hearing and restoring hearing of humans and animals after damage and loss of sensory hair cells in an organ of Corti based on regeneration biology includes administering a therapeutically effective amount of a compound including aminoalkyloxazole and aminoalkylthiazole carboxylic acid amides, or a pharmaceutically acceptable salt, a stereoisomer, a stereoisomer mixture, a tautomer or a prodrug compound thereof, directly or indirectly to damaged tissue structures in a cochlea, optionally, by transtympanal injection into a middle ear, by application to a round or oval window of an inner ear or by injection into the inner ear.